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Figure 1: Anti-mitotic drugs sensitize tumor cells to TRAIL-induced apoptosis. 
Upper: MDA-MB231 (A) and  HeLa  (B) cells were  incubated for 15h (A) or 21h (B) with different anti-mitotic drugs before the addition of TRAIL (500 ng/mL or 50 
ng/mL,respectively).  Apoptosis was measured 6h after TRAIL addition as the percentage of cells with sub-G1 DNA content by flow citometry.  Lower: Cells were incubated for 
24h with same treatments as in the upper panels. 
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MDA-MB231 HeLa (A) (B) Cell cycle deregulation is a feature of tumor cells. Most of the current therapeutic 
strategies are based on the perturbation of the cell cycle, especially during mitosis. “Anti-
mitotic drugs” perturb the correct assembly of the mitotic spindle triggering the activation 
of the spindle assembly checkpoint (SAC), which results in a mitotic arrest and eventually, 
cell death. However, sometimes cells go out of mitosis by “slippage”, being one of the main 
mechanism of resistance to these treatments. We have already reported that microtubule 
poisons treatment sensitizes tumor cells to TRAIL- induced apoptosis and also that FLIP 
down-regulation induced by these treatments is the key event in this sensitization. 
In this study we demonstrate that both FLIP down-regulation and sensitization to 
TRAIL- induced apoptosis are induced by mitotic arrest independently of checkpoint 
activation. Moreover, although targeting mitotic exit has recently been proposed as a better 
strategy to kill tumor cells than conventional anti-mitotic drugs, we have observed that 
treatments based on combination of mitotic arrest-inducing regimes with TRAIL are much 
more effective against tumor cells, highlighting the potential therapeutic benefit of the use 
of this combination against tumor cells. Finally, we show that CDK1/Cyclin B complex, but 
no other mitotic kinases, seems to have a role in FLIP down-regulation, as FLIP levels 
inversely correlate with CDK1 activity in mitosis.  
 
Abstract 
Figure 2: Inactivation of mitotic checkpoint prevents FLIP down-regulation 
and sensitization to TRAIL- induced apoptosis by antimitotic agents. 
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(A) MDA-MB231 cells were transfected for 48h 
with siRNA. After this time, cells were treated with 
Nocodazole for 24h.  
B) Cells transfected as described in (A) were 
incubated with Nocodazole before treatment with 
TRAIL. 
(A) FLIP downregulation is blocked in presence of 
nocodazole in cells with compromised SAC. 
(B) SAC inactivation reduces sensitization to 
TRAIL by nocodazole. 
Figure 4: Role of CDK1 in FLIP downregulation during mitosis. 
(B) During mitotic arrest, FLIP levels correlates 
inversely with CDK1/Cyclin B activity. 
(A) FLIP is degraded by proteasome during 
mitotic arrest. 
(A) MDA-MB231 cells were synchronised at 
the G2/M boundary by RO-3306 (10 mM, 20 
h), a selective CDK1 inhibitor. Then, cells were 
released in fresh medium in presence of 
Nocodazole (250 ng/mL). After 3h, rounded-up 
mitotic cells were collected (control cells) and 
re-plated in nocodazole-containing media and 
in presence or absence of a proteasome 
inhibitor, MG132 (10 mM). For western blot 
analysis cells were collected after indicated 
times. 
(B) MDA-MB231 cells were  incubated for 24h 
with nocodazole (250 ng/mL) and  a specific 
CDK1 inhibitor, RO-3306, at the indicated  
concentrations. For both untreated cells and 
cells treated with RO-3306 10 mM only 
adherent cells were collected, as at this 
concentration, cells are arrested in G2. By the 
oppossite, only mitotic cells were collected by 
“shake-off” in the  rest of conditions . 
(C) MDA-MB231 cells were treated with 
nocodazole (250 ng/mL) for 15h and then, 
different mitotic kinases inhibitors were added 
for 9h more. BI 2536 (Plk1 inhibitor, 100nM) 
,ZM 447439 (Aurora A and B inhibitor, 2 mM). 
 
  
(C) Plk1 inhibition or Aurora inhibition 
does not affect to FLIP downregulation 
during mitosis.  
Figure 3: Mitotic arrest, independently of checkpoint activation, induces sensitization to TRAIL- induced apoptosis. 
(A) Cdc20 knockdown- induced mitotic arrest , SAC independent, is sufficient to sensitize to TRAIL-induced apoptosis 
(B) Overexpression of nondegradable Cyclin B induces mitotic arrest and sensitizes tumor cells to TRAIL- 
induced apoptosis 
(A) HeLa cells were transfected with either Control or Cdc20 siRNA and synchronize in G1/S by thymidine block for 24h. Then, cells were released in fresh 
medium and TRAIL (50 ng/mL) was added after 15h. Cell cycle progression and apoptosis was analyzed by time-lapse microscopy. Upper: Images 
representatives are shown, “t” indicates the time of TRAIL addition. Lower right: Analysis of cell survival. Lower left: Cells were collected for western blot 
analysis after 24h of the release in presence or absence of Nocodazole (250 ng/mL) and with or without a Mps1 inhibitor, Reversine (1 mM). 
(B) U2OS cells that express tetracycline-inducible nondegradable Cyclin B were synchronized in G1/S by thymidine block for 24h. Then, cells 
were released in fresh medium in presence or absence of tetracycline. After 1h, TRAIL (250 ng/mL) was added. Cell cycle progression and 
apoptosis was analyzed by time-lapse microscopy.. Upper: Images representatives are shown, “t” indicates the time of release. Lower right: 
Analysis of cell survival. Lower left: Cells were collected for western blot analysis after 24h of the release in presence or absence of  tetracycline 
and  nocodazole (250 ng/mL). “As” = asynchronous cells, “Ad” = adherent cells, “M” = mitotic cells 
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Drugs inducing mitotic checkpoint activation and mitotic arrest, downregulate FLIP levels and sensitize  tumor cells to TRAIL-induced apoptosis. 
 Inactivation of checkpoint machinery prevents sensitization to TRAIL- induced apoptosis by anti-mitotic drugs. 
 Mitotic arrest, independently of SAC activation, is sufficient to induce both FLIP downregulation and sensitization to TRAIL-induced apoptosis. 
 Combination of drugs that induce mitotic arrest with TRAIL is a much more effective killing tumor cells than either of these treatments alone. 
 CDK1, but not other mitotic kinases, seems to be involved in FLIP downregulation during mitotic arrest. 
 
Conclusions 
